Beneficial Effect of Etidronate Therapy in Immobilized Hip Fracture Patients[Retracted]

Abstract

Etidronate therapy inhibits bone resorption and improves calcium balance, and such therapy may prevent bone loss and reduce the risk of subsequent hip fracture.

Retracted: Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial

“…The average values of metacarpal BMD in the two patient groups were lower as compared to the reference range of normal Japanese population. 8,19 As shown in Table 2, in the two patient groups, the baseline values of serum 25-OHD and 1,25-[OH] 2 D concentrations were low, while serum-ionized calcium or urinary D-Pyr was high as compared to the reference range of normal Japanese population. 8,19 When the placebo and alendronate groups were analyzed together, BMD correlated with 25-OHD concentrations (r ϭ 0.195; P Ͻ 0.001), while the BMD correlated negatively with calcium concentrations (r ϭ Ϫ0.169; P Ͻ 0.01) and D-Pyr concentrations (r ϭ Ϫ0.308; P Ͻ 0.001).…”

“…8,19 As shown in Table 2, in the two patient groups, the baseline values of serum 25-OHD and 1,25-[OH] 2 D concentrations were low, while serum-ionized calcium or urinary D-Pyr was high as compared to the reference range of normal Japanese population. 8,19 When the placebo and alendronate groups were analyzed together, BMD correlated with 25-OHD concentrations (r ϭ 0.195; P Ͻ 0.001), while the BMD correlated negatively with calcium concentrations (r ϭ Ϫ0.169; P Ͻ 0.01) and D-Pyr concentrations (r ϭ Ϫ0.308; P Ͻ 0.001). As we previously reported, 11 there were correlations between Hoehn and Yahr stage and serum-ionized calcium (r ϭ 0.324; P Ͻ 0.001), serum 25-OHD (r ϭ Ϫ0.248; P Ͻ 0.001), urinary level of D-Pyr (r ϭ 0.262; P Ͻ 0.001), and BMD (r ϭ Ϫ0.154; P Ͻ 0.01).…”

“…The nor-mal ranges of the BMD and biochemical indexes in elderly women were described in Table 2. 8,19 The two patient groups were followed for 2 years. In addition to their overall clinical status, careful evaluation for a possible hip fracture was performed every 4 weeks.…”

Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials

“…Figure 1 illustrates the process of study selection. Ten trials [25][26][27][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] were finally designed to evaluate the effect of the timing of BP initiation after surgery for fracture healing and fulfilled the inclusion criteria for published studies (including safety reports), including a large-scale multicultural RCT with a large number of reports written about it [26,27,[38][39][40][41][42][43][44][45][46].…”

“…Four trials used alendronate [29,31,34,37], three trials used zoledronic [25,32,33,46], two trials used risedronate [30,35], and one trial used etidronate [36]; the schedule varied as reflected in Table 2. The control group included the delayed use of BPs or use placebo instead of BPs or no therapy.…”